Mymd Pharmaceuticals (NASDAQ:QCLS) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen lowered shares of Mymd Pharmaceuticals (NASDAQ:QCLS) from a sell rating to a strong sell rating in a report published on Sunday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a research note on Friday, August 7th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Mymd Pharmaceuticals Stock Performance

Shares of Mymd Pharmaceuticals stock opened at $2.77 on Friday. Mymd Pharmaceuticals has a 52 week low of $2.50 and a 52 week high of $10.78. The business has a 50 day moving average of $3.44. The stock has a market capitalization of $11.55 million, a P/E ratio of -0.13 and a beta of 2.16.

Mymd Pharmaceuticals (NASDAQ:QCLS) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.79) earnings per share for the quarter.

Mymd Pharmaceuticals Company Profile

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.